ANXA6 and cancer: In addition, drug-induced AnxA6 upregulation, delivery of recombinant AnxA6 or AnxA6-targeting antibodies might lead to the development of novel treatment options in lipid disorders, liver dysfunction, several cancers and muscular damage (Section 7.4, Section 7.5 and Section 7.6).